{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:57:40Z","timestamp":1790038660711,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1995,11,1]],"date-time":"1995-11-01T00:00:00Z","timestamp":815184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1995,11]]},"DOI":"10.1007\/bf00685802","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T08:31:06Z","timestamp":1101717066000},"page":"513-523","source":"Crossref","is-referenced-by-count":40,"title":["Phase I clinical trial of continuous infusion cyclopentenyl cytosine"],"prefix":"10.1007","volume":"36","author":[{"given":"Pedro M.","family":"Politi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dahut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Harry","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Setser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen J.","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F.","family":"Arbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Brammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Grem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF00685802_CR1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1021\/jm00117a004","volume":"31","author":"VE Marquez","year":"1988","unstructured":"Marquez VE, Lim M-I, Treanor SP, Plowman J, Priest MA, Markovac A, Khan MS, Kaskar B, Driscoll JS (1988) Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. J Med Chem 31:1687","journal-title":"J Med Chem"},{"key":"BF00685802_CR2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/jm00378a002","volume":"27","author":"M-I Lim","year":"1984","unstructured":"Lim M-I, Moyer JD, Cysyk RL, Marquez VE (1984) Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase. J Med Chem 27:1536.","journal-title":"J Med Chem"},{"key":"BF00685802_CR3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0021-9258(19)85001-9","volume":"264","author":"GJ Kang","year":"1989","unstructured":"Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim H-Y, Marquez VE, Johns DG (1989) Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J Biol Chem 264:713","journal-title":"J Biol Chem"},{"key":"BF00685802_CR4","first-page":"3733","volume":"51","author":"H Ford Jr","year":"1991","unstructured":"Ford H Jr, Cooney DA, Ahluwalia GS, Hao Z, Rommel ME, Hicks L, Dobyns KA, Tomaszewski JE, Johns DG (1991) Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res 51:3733","journal-title":"Cancer Res"},{"key":"BF00685802_CR5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0006-2952(92)90218-8","volume":"43","author":"LK Yee","year":"1992","unstructured":"Yee LK, Allegra CJ, Trepel JB, Grem JL (1992) Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells. Biochem Pharmacol 43:1587","journal-title":"Biochem Pharmacol"},{"key":"BF00685802_CR6","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/0006-2952(85)90539-8","volume":"34","author":"RI Glazer","year":"1985","unstructured":"Glazer RI, Knode MC, Lim M-I, Marquez VE (1985) Cyclopentenyl cytidine analogue. An inhibitor of cytidine triphosphate synthesis in human colon carcinoma cells. Biochem Pharmacol 34:2535","journal-title":"Biochem Pharmacol"},{"key":"BF00685802_CR7","first-page":"3325","volume":"46","author":"JD Moyer","year":"1986","unstructured":"Moyer JD, Malinowski NM, Treanor SP, Marquez VE (1986) Antitumor activity biochemical effects of cyclopentenyl cytosine in mice. Cancer Res 46:3325","journal-title":"Cancer Res"},{"key":"BF00685802_CR8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/0006-2952(86)90301-1","volume":"35","author":"RI Glazer","year":"1986","unstructured":"Glazer RI, Cohen MB, Hartman KD, Knode MC, Lim M-I, Marquez VE (1986) Induction of differentiation in the human promyelocytic leukemia cell line HL-60 by the cyclopentenyl analogue of cytidine. Biochem Pharmacol 35:1841","journal-title":"Biochem Pharmacol"},{"key":"BF00685802_CR9","first-page":"284","volume":"34","author":"WL Dahut","year":"1993","unstructured":"Dahut WL, Allegra CJ, Grem JL (1993) Modulation of cyclopentenyl cytosine toxicity by cytidine and dipyridamole in human colon cancer cells. Proc Am Assoc Cancer Res 34:284","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00685802_CR10","first-page":"441","volume":"31","author":"JE Tomaszewski","year":"1990","unstructured":"Tomaszewski JE, Heath JE, Grieshaber CK, Page JG (1990) Toxicity of cyclopentenyl cytosine (NSC-375575) in CD2F1 mice and Fischer-344 rats. Proc Am Assoc Cancer Res 31:441","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00685802_CR11","first-page":"442","volume":"31","author":"JG Page","year":"1990","unstructured":"Page JG, Heath JE, Tomaszewski JE, Grieshaber CK (1990) Toxicity and pharmacokinetics of cyclopentenyl cytosine (NSC 375575) in beagle dogs. Proc Am Assoc Cancer Res 31:442","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00685802_CR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00194539","volume":"9","author":"DS Zaharko","year":"1991","unstructured":"Zaharko DS, Kelley JA, Tomaszewski JE, Hegedus L, Hartman NR (1991) Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics. Invest New Drugs 9:9","journal-title":"Invest New Drugs"},{"key":"BF00685802_CR13","first-page":"7915","volume":"50","author":"SM Blaney","year":"1990","unstructured":"Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG (1990) Pharmacokinetics and metabolism of cyclopentenyl cytosine (CPE-C) in nonhuman primates. Cancer Res 50:7915","journal-title":"Cancer Res"},{"key":"BF00685802_CR14","first-page":"3503","volume":"52","author":"S Blaney","year":"1992","unstructured":"Blaney S, Balis FM, Grem J, Cole DE, Adamson PC, Poplack DG (1992) Modulation of the cytotoxic effect of cyclopentenyl-cytosine by its primary metabolite, cyclopentenyl uridine. Cancer Res 52:3503","journal-title":"Cancer Res"},{"key":"BF00685802_CR15","first-page":"353","volume":"11","author":"PL Russ","year":"1992","unstructured":"Russ PL, Hegedus L, Kelley JA, Barchi JJ, Marquez VE (1992) The controlled stereospecific reduction of cyclopentenyl cytosine to carbodine and isocarbodine. Nucleosides Nucleotides 11:353","journal-title":"Nucleosides Nucleotides"},{"key":"BF00685802_CR16","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Garibaldi","year":"1982","unstructured":"Garibaldi M, Perrier D (1982) In: Swarbrik J (ed) Pharmacokinetics, 2nd edn, vol 15, Marcel Dekker. New York, pp","edition":"2nd edn"},{"key":"BF00685802_CR17","first-page":"5591","volume":"48","author":"PH Fischer","year":"1988","unstructured":"Fischer PH, Willson JKV, Risueno C, Tutsch K, Bruggink J, Ranhosky A, Trump DL (1988) Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion. Cancer Res 48:5591","journal-title":"Cancer Res"},{"key":"BF00685802_CR18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00172020","volume":"4","author":"WJ Moriconi","year":"1986","unstructured":"Moriconi WJ, Slavik M, Taylor S (1986) 3-deazauridine (NSC 126849), an interesting modulator of biochemical response. Invest New Drugs 4:67","journal-title":"Invest New Drugs"},{"key":"BF00685802_CR19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0163-7258(90)90094-I","volume":"46","author":"GS Ahluwalia","year":"1990","unstructured":"Ahluwalia GS, Grem JL, Hao Z, Cooney DA (1990) Metabolism and action of amino acid analog anticancer agents. Pharmacol Ther 46:243.","journal-title":"Pharmacol Ther"},{"key":"BF00685802_CR20","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.1984.2.9.1064","volume":"2","author":"PJ O'Dwyer","year":"1984","unstructured":"O'Dwyer PJ, Alonso MT Leyland-Jones B (1984) Acivicin: a new glutamine antagnosit in clinical trials. J Clin Oncol 2: 1064","journal-title":"J Clin Oncol"},{"key":"BF00685802_CR21","first-page":"389","volume":"59","author":"JJ Lokich","year":"1975","unstructured":"Lokich JJ, Chawla PL, Jaffe N, Frei E III (1975) Phase I evaluation of cyclocytidine (NSC-145668). Cancer Chemother Rep 59:389","journal-title":"Cancer Chemother Rep"},{"key":"BF00685802_CR22","first-page":"180","volume-title":"Pharmacologic principles of cancer treatment","author":"RA Bender","year":"1990","unstructured":"Bender RA, Hamel E, Hande KR (1990) Plant alkaloids. In: Chabner BA, Collins JM (eds) Pharmacologic principles of cancer treatment, 2nd edn. W. B. Saunders, Philadelphia, p 180","edition":"2nd edn"},{"key":"BF00685802_CR23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00001813-199302000-00001","volume":"4","author":"MC Bibby","year":"1993","unstructured":"Bibby MC, Double JA (1993) Flavone acetic acid-from laboratory to clinic and back. Anticancer Drugs 4:3","journal-title":"Anticancer Drugs"},{"key":"BF00685802_CR24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/jnci\/80.14.1095","volume":"80","author":"JL Grem","year":"1988","unstructured":"Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M (1988) Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst 80:1095","journal-title":"J Natl Cancer Inst"},{"key":"BF00685802_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0006-2952(94)00470-6","volume":"49","author":"RL Cysyk","year":"1994","unstructured":"Cysyk RL, Malinowski N, Marquez V, Zaharevitz D, August EM, Moyer JD (1994) Cyclopentenyl uracil: an effective inhibitor of uridine salvage in vivo. Biochem Pharmacol 49:203","journal-title":"Biochem Pharmacol"},{"key":"BF00685802_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0006-2952(94)00490-0","volume":"49","author":"H Ford Jr","year":"1994","unstructured":"Ford H Jr, Driscoll JS, Hao Z, Dobyns KA, Rommel ME, Stowe E, Anderson JO, Waud WR, Plowman J, Johns DG, Cooney DA (1994) Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity. Biochem Pharmacol 49:173","journal-title":"Biochem Pharmacol"},{"key":"BF00685802_CR27","first-page":"7279","volume":"50","author":"JL Grem","year":"1990","unstructured":"Grem JL, Allegra CJ (1990) Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and cytosine arabinoside by cyclopentenyl cytosine. Cancer Res 50:7279","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685802\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685802.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:29:04Z","timestamp":1625012944000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["BF00685802"],"URL":"https:\/\/doi.org\/10.1007\/bf00685802","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]}}}